EnCapsid Therapeutics

EnCapsid Therapeutics is a private Boston-area gene therapy biotechnology company developing engineered adeno-associated virus (AAV) delivery vectors for genetic medicine. The company's core platform uses site-specific conjugation and unnatural amino acid incorporation to precisely modify natural or engineered AAV capsids, with the goal of improving tissue targeting, reducing neutralizing antibody recognition, and expanding payload flexibility. EnCapsid positions this approach as a synthetic virology platform that can enhance existing gene therapies and enable new delivery strategies, including more efficient CRISPR-Cas9 delivery. Publicly available information suggests the company remains at the preclinical/platform stage rather than in human clinical development. The business appears to have originated as a spinout backed by Tiger Gene and is led by co-founder John Boyce.